文 献1）婦人科腫瘍委員会（2021）、「2019年患者年報」、3）Hensley ML, Chavan SS, Solit DB, Murali R, Soslow R, Chiang S, et al. Genomic landscape of uterine sarcomas defined through prospective clinical sequencing. Clin Cancer Res 2020; 26: 3881-8.日産婦会誌; 73(7): 796-852.2）Roberts ME, Aynardi JT, Chu CS. Uterine leiomyosarcoma: a review of the literature and update on management options. Gynecol Oncol 2018; 151: 562-72.4）Yoshida K, Yokoi A, Yamamoto T, Hayashi Y, Nakayama H, Yokoi T, et al. Aberrant activation of cell cycle-related kinases and the potential therapeutic impact of PLK1 or CHEK1 inhibition in uterine leiomyosarcoma. Clin Cancer Res 2022; 28: 2147-59.5）Yoshida K, Yokoi A, Kitagawa M, Sugiyama M, Yamamoto T, Nakayama J, et al. Downregulation of miR-10b-5p facilitates the proliferation of uterine leiomyosarcoma cells: A microRNA sequencing-based approach. Oncol Rep 2023; 49: 86.6）Shan W, Akinfenwa PY, Savannah KB, Kolomeyevskaya N, Laucirica R, Thomas DG, et al. A small-molecule inhibitor targeting the mitotic spindle checkpoint impairs the growth of uterine leiomyosarcoma. Clin Cancer Res 2012; 18: 3352-65.7）Hyman DM, Sill MW, Lankes HA, Piekarz R, Shahin MS, Ridgway MR, et al. A phase 2 study of alisertib (MLN8237) in recurrent or persistent uterine leiomyosarcoma: an NRG oncology/gynecologic oncology group study 0231D. Gynecol Oncol 2017; 144: 96-100.8）Otto T, Sicinski. Cell cycle proteins as promising targets in cancer therapy. Nat Rev Cancer 2017; 17: 93-115.9）Mross K, Dittrich C, Aulitzky WE, Strumberg D, Schutte J, Schmid RM, et al. A randomised phase Ⅱtrial of the Polo-like kinase inhibitor BI 2536 in chemonaive patients with unresectable exocrine adenocarcinoma of the pancreas—a study within the Central European Society Anticancer Drug Research (CESAR) collaborative network. Br J Cancer 2012; 107: 280-6.10）Lee JM, Nair J, Zimmer A, Lipkowitz S, Annunziata CM, Merino MJ, et al. Prexasertib, a cell cycle checkpoint kinase 1 and 2 inhibitor, in BRCA wild-type recurrent high-grade serous ovarian cancer: a first-in-class proof-of-concept phase 2 study. Lancet Oncol 2018; 19: 207-15.11）Yoshida K, Yamamoto Y, Ochiya T. miRNA signaling networks in cancer stem cells. Regen Ther 2021; 17: 1-7.12）Shi G, Perle MA, Mittal K, Chen H, Zou X, Narita M, et al. Let-7 repression leads to HMGA2 overexpression in uterine leiomyosarcoma. J Cell Mol Med 2009; 13: 3898-905.13）Li Y, Chen D, Li Y, Jin L, Liu J, Su Z, et al. Oncogenic cAMP responsive element binding protein is overexpressed upon loss of tumor suppressive miR-10b-5p and miR-363-3p in renal cancer. Oncol Rep 2016; 35: 1967-78.49
元のページ ../index.html#63